Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
 
Sign in
Join now
featured
Published in COVID-19 and
1 other channel

Journal Scan / Research · July 25, 2022

Effect of a 2-Week Interruption in Methotrexate Treatment vs Continued Treatment on COVID-19 Booster Vaccine Immunity in Adults With Inflammatory Conditions

The Lancet Respiratory Medicine

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Emmett Kistler MD

The Lancet Respiratory Medicine
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial
Lancet Respir Med 2022 Jun 27;[EPub Ahead of Print], A Abhishek, RJ Boyton, N Peckham, Á McKnight, LC Coates, J Bluett, V Barber, L Cureton, A Francis, D Appelbe, L Eldridge, P Julier, AM Valdes, T Brooks, I Rombach, DM Altmann, JS Nguyen-Van-Tam, HC Williams, JA Cook

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated